Akut Lösemilere Yaklaşım

Authors

Yunus Tekin
https://orcid.org/0000-0002-1494-178X
Mehmet Serdar Yıldırım

Synopsis

Acute leukemias are heterogeneous diseases caused by the malignant transformation of hematopoietic progenitor cells, leading to blocked maturation, increased proliferation, and impaired apoptosis. In its 2016 classification, the World Health Organization (WHO) shifted the diagnostic and subtyping focus from morphological findings to genetic abnormalities. Although detecting 20% or more blasts in bone marrow aspirates is the standard diagnostic threshold, certain specific cytogenetic abnormalities serve as exceptions. Acute Myeloblastic Leukemia (AML) is the most common acute leukemia in adults, with its incidence increasing with age. Environmental factors, genetic disorders, prior chemo/radiotherapy, and underlying hematologic conditions are established risk factors. Clinical manifestations stem from anemia, thrombocytopenia, leukocyte alterations, and leukemic organ infiltration. Diagnosis relies on morphological, immunophenotypic, and genetic analyses of peripheral blood and bone marrow. AML management comprises remission induction followed by risk-stratified consolidation treatments, including high-dose cytarabine or stem cell transplantation. Acute Lymphoblastic Leukemia (ALL) is characterized by the rapid proliferation of immature lymphoid cells, with tyrosine kinase inhibitors integrated into the regimen for Ph(+) ALL cases. Early recognition and management of acute complications such as tumor lysis syndrome, disseminated intravascular coagulation, hyperleukocytosis, leukostasis, and febrile neutropenia are critical throughout the clinical course.

References

Lichtman MA. Acute myelogenous leukemia. In: Beutler E, Lichtman MA, Coller BC, Kipps TJ, eds. Williams Hematology, 5th ed. New York: McGraw-Hill, Inc; 1995. p.272-98.

Beksaç M. Akut miyeloid lösemi. Türkiye Klinikleri Hematoloji 2004;2:1-9.

Henderson ES. Acute leukemia: General considerations. In: Williams WJ, Beutler E, Erslev AJ, Lichtman MA, eds. Williams Hematology, 4rd ed. New York: McGraw-Hill, Co; 1990. p.236- 50.

Swerdlow SH CE, Harris NL, et al. WHO classification of Tumors of Haematopoietic and Lymphoid Tissues. IARC Press, Lyon; 2008.

Arber DA, Orazi A, Hasserjian R, Thiele J, Borowitz MJ, Le Beau MM, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood 2016;127(20):2391-2405.

Jabbour EJ, Estey E, Kantarjıan HM. Adult acute myeloid leukemia. Mayo Clin Proc 2006;81:247-60.

NCCN Practice Guidelines in Oncology - v.1.2006.

Liesveld JL, Lichtman MA. Acute myelogenous leukemia In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT eds. Williams Hematology. 7th ed. USA: Mc-Graw-Hill; 2006. p.1183-236.

Deschler B, Lübbert M. Acute myeloid leukemia: epidemiology and etiology. Cancer 2006;107:2099-107.

Kossman SE, Weiss MA. Acute myelogenous leukemia after exposure to strontium-89 for the treatment of adeno carcinoma of the prostate. Cancer 2000;88:620-4.

Pedersen-Bjergaard J, Christiansen DH, Andersen MK, Skovby F. Causality of myelodysplasia and acute myeloid leukemia and their genetic abnormalities. Leukemia 2002; 16:2177-84.

Martinelli G, Vianelli N, De Vivo A, Ricci P, Remiddi C, Testoni N, et al. Granulocytic sarcomas: Clinical, diagnostic and therapeutic aspects. Leuk Lymphoma 1997;24:349.

Cohen PR, Talpaz M, Kurzrock R. Malignancy associated Sweet’s syndrome review of the world literature. J Clin Oncol 1988;6: 1887-987.

Holmes R, Keating MJ, Cork A, Broach Y, Trujillo J, Dalton WT Jr, et al. An uniqu e pattern of central nervous system leukemia in acute myelomonocytic leukemia associated with inv(16)(p13q22). Blood 1985;65:1071-8.

Pileri SA, Ascani S, Cox MC, Campidelli C, Bacci F, Piccioli M, et al. Myeloid Sarcoma: clinicopathologic, phenothypic and cytogenetic analysis of adult 92 patients. Leukemia 2007;21:340-50.

Wiernik PH. Ekstramedullary manifestations of adult leukemia. Am Cancer Society of Atlas Clinical Oncology adult Leukemias. London BC Decker; 2001. p.275-305.

Keidan RD, Fanning J, Gatenby RA, Weese JL.. Reccurent Thyphlitis. A disease resulting from aggressive chemotherapy. Dis Colon Rectum 1989;32:206-9.

Cheson BD, Bennett JM, Kopecky KJ, et al. Revised recommendations of the International working group for diagnosis, standardization of response criteria, treatment outcomes, and reporting standards for therapeutic trials in acute myeloid leukemia. J Clin Oncol 2003;21:4642-9.

ESMO Minimum Clinical Recommendations for the diagnosis, treatment and follow-up of acute myeloblastic leukemia (AML) in adult patients. Annals of Oncology 2005;16(Supplement 1):i48-i49.

British Committee for Standards in Haematology; Milligan DW, Grimwade D, Cullis JO et al. Guidelines on the management of acute myeloid leukaemia in adults. British Journal of Haematology, 135, 450-74.

(Cassileth PA, Lynch E, Hines JD, Oken MM, Mazza JJ, Bennett JM, McGlave PB,et al. Varying intensity of postremission therapy in acute myeloid leukemia. Blood 1992;79(8): 1924. )

(Weick JK, Kopecky KJ, Appelbaum FR, Head DR, Kingsbury LL, Balcerzak SP,et al. A randomized investigation of high-dose versus standard-dose cytosine arabinoside with daunorubicin in patients with previously untreated acute myeloid leukemia: a Southwest Oncology Group study. Blood 1996;88(8): 2841.

Ulusal Hematoloji Derneği Akut Lösemiler Tanı ve Tedavi Klavuzu 2018 Sürüm 1.02/Ekim 2018

(Cornelissen JJ, van Putten WL, Verdonck LF, Theobald M, Jacky E, Daenen SM, et al. Results of a HOVON/SAKK donor versus nodonor analysis of myeloablative HLA-identical sibling stem cell transplantation in first remission acute myeloid leukemia in young and middle-aged adults: benefits for whom? Blood 2007;109(9):3658.)

Vitale A, Guarini A, Chiaretti S, Foa R. The changing scene of adult acute lymphoblastic leukemia. Curr Opin Oncol. 2006;18:652-9.

Gale RE,Wainscoat JS: Clonal analysis using X-linked DNA polymorphisms. Br. J Haematol 1993;85;2.

Pui CH. Acute lymphoblastic leukemia, In: Lichtman MA, Beutler E, Kipps TJ, Seligsohn U, Kaushansky K, Prchal JT eds. Wiliams Hematology. 7th ed. USA McGraw-Hill; 2006 p.1321-42.

Jabbour EJ, Faderl S, Kantarjian HM. Adult acute lymphoblastic leukemia. Mayo Clin Proc 2005;80:1517-27.

Faderi S, Jeha S, Kantarjian HM. The biology and therapy of adult acute lymphoblastic leukemia. Cancer 2003;7:1337-54.

Attarbaschi A, Mann G, Dworzak M, et al. Mediastinal mass in childhood T-cell acute lymphoblastic leukemia: signifi-cance and therapy response. Med Pediatr Oncol. 2002;39:558-65.

Cortes J. Central nervous system involvement in adult acute lymphocytic leukemia. Hematol Oncol Clin North Am. 2001;15:145-62.

WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues, revised 4th edition, Swerdlow SH, Campo E, Harris NL, et al. (Eds), International Agency for Research on Cancer (IARC), Lyon 2017.

Schelling JR, Ghandour FZ, Strickland TJ, Sedor JR. Management of tumor lysis syndrome with standard continuous arterio venous hemodialysis case report and a review of literature. Ren Fail 1998;20:635-44.

Nicholin G. Emergencies and their manangement. Eur J Can cer 2000;38:1365- 77.

Published

May 20, 2021

License

License